Generic Product News (December 2016)

Pharmacy TimesDecember 2016 Heart Health
Volume 82
Issue 12

Read about the new generic products featured in December.


Marketed by: Glenmark Pharmaceuticals, Inc

Compare to: Xylocaine Ointment, 5% (AstraZeneca)

Indication: Glenmark Pharmaceuticals, Inc, has announced final approval for its generic version of Xylocaine Ointment, 5%. Lidocaine Ointment USP, 5%, is indicated for production of anesthesia of accessible mucous membranes of the oropharynx. It is also used as an anesthetic lubricant for intubation and temporary relief of pains associated with minor burns, including sunburn, skin abrasions, and insect bites.

Dosage Forms: Topical

For More Information:


Marketed by: Amneal

Compare to: Merrem (AstraZeneca)

Indication: Amneal has launched Meropenem for Injection, USP (I.V.), an AP-rated generic equivalent to Merrem. Meropenem is indicated for the treatment of complicated skin and skin structure infections, intraabdominal infections, and bacterial meningitis.

Dosage Forms: Injection: 500- mg and 1-g per vial strengths in 10-count packages

For More Information:


Marketed by: Camber

Compare to: Crestor (AstraZeneca)

Indication: Camber has announced that it has launched the generic version of Crestor tablets. Rosuvastatin indicated to treat high cholesterol and triglyceride levels.

Dosage Forms: Tablets: 5, 10, and 20 mg in 90-count bottles; 40 mg in 30-count bottles

For More Information:


Marketed by: Camber

Compare to: Avodart (GlaxoSmithKline)

Indication: Camber has launched the generic version of Avodart capsules. Dutasteride is indicated for the treatment of an enlarged prostate.

Dosage Forms: Capsules: 0.5 mg in 30- and 90-count bottles

For More Information:

Related Videos
View All
© 2023 MJH Life Sciences

All rights reserved.